Modality
mAb
MOA
VEGFi
Target
IL-13
Pathway
PI3K/AKT
GA
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
~Mar 2024
→ ~Jun 2025
Phase 2
Sep 2025
→ Mar 2028
Phase 2Current
NCT07110862
714 pts·GA
2025-09→2028-03·Recruiting
714 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-071.9y awayPh3 Readout· GA
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Recruit…
Catalysts
Ph3 Readout
2028-03-07 · 1.9y away
GA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07110862 | Phase 2/3 | GA | Recruiting | 714 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |